FDA approves first gene-editing treatment for human illness

"I'm ecstatic. It's a blessing that they approved this therapy," said Victoria Gray, the first person in the U.S. to undergo CRISPR gene-editing for sickle cell, of the Food and Drug Administration's decision. (Orlando Gili)

In a landmark decision, the Food and Drug Administration Friday approved the first gene-editing treatment to alleviate human illness.

The FDA approved two gene therapies for anyone 12 and older suffering from the most severe form of sickle cell disease, a brutal blood disorder that has long been neglected by medical research.